Tumor Mutation Burden as Biomarker: All-Systems-Go or Too Early? Tumor Mutation Burden as Biomarker: All-Systems-Go or Too Early?

Drs West, Patel, and Bauml debate the use of TMB analysis in choosing a treatment regimen for NSCLC.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news